title: [New trends in the treatment of amyloidosis].
abstract: Amyloidosis is a clinical disorder caused by extracellular deposition of proteins that are normally soluble as insoluble fibrils that damage different organs. More than 20 proteins can form amyloid deposits. All types of amyloid fibrils have a secondary structure with a β folded shape that is characteristic and makes them to adopt a green birefringence after stained with Congo red and viewed under cross-polarized light. Amyloidosis can be acquired or hereditary, systemic or localized, and are classified by the fibril precursor protein. Advances in the knowledge of the pathogenesis of amyloidosis allows the development of new diagnostic and therapeutical schemes that are currently under investigation.
authors.affiliation: Unidad de Enfermedades Autoinmunes y Sistémicas, Servicio de Medicina Interna, Hospital General Universitario Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España. ferranmartinezvalle@gmail.com
authors.forename: Fernando
authors.initials: F
authors.lastname: Martínez-Valle
authors.forename: Mercedes
authors.initials: M
authors.lastname: Gironella-Mesa
authors.forename: Roser
authors.initials: R
authors.lastname: Solans-Laqué
mesh_terms: D000682:Amyloid / Q000737:chemistry; D000686:Amyloidosis / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D002264:Carboxylic Acids / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D011407:Propane / Q000031:analogs & derivatives / Q000627:therapeutic use; D011487:Protein Conformation; D011759:Pyrrolidines / Q000627:therapeutic use; D013451:Sulfonic Acids / Q000627:therapeutic use
chemical_list: D000682:Amyloid; D002264:Carboxylic Acids; D011759:Pyrrolidines; C455899:R-1-(6-(R-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid; D013451:Sulfonic Acids; C520274:eprodisate; D011407:Propane